Dendreon Corporation, is a biotechnology company. The Company is focused on discovery, development and commercialization of therapeutics for cancer treatment. The Company's product portfolio includes cellular immunotherapies and small molecule product candidate that could be applicable to treating multiple types of cancers. The Company's product PROVENGE (sipuleucel-T), is an autologous cellular immunotherapy for the treatment of asymptomatic and minimally symptomatic, metastatic, castrate-resistant hormone-refractory prostate cancer. Other potential product candidates include investigational active cellular immunotherapy, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu; active cellular immunotherapies directed at carbonic anhydrase 9, an antigen highly expressed in renal cell carcinoma, and carcinoembryonic antigen, an antigen expressed in colorectal and other cancers.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
CIKN/A
Phone+1-206-2197815
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Dendreon (OTCMKTS:DNDNQ) Frequently Asked Questions
What is Dendreon's stock symbol?
Dendreon trades on the OTCMKTS under the ticker symbol "DNDNQ."
How were Dendreon's earnings last quarter?
Dendreon Co. (OTCMKTS:DNDNQ) posted its quarterly earnings results on Monday, November, 10th. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.04. The biotechnology company had revenue of $73.10 million for the quarter, compared to the consensus estimate of $78.72 million. The company's revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.44) earnings per share. View Dendreon's Earnings History.
Has Dendreon been receiving favorable news coverage?
News coverage about DNDNQ stock has trended somewhat negative recently, according to InfoTrie. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dendreon earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the stock's share price in the next several days.
What other stocks do shareholders of Dendreon own?
How do I buy shares of Dendreon?
Shares of DNDNQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dendreon's official website?
How can I contact Dendreon?
Dendreon's mailing address is 601 Union St Ste 4900, SEATTLE, WA 98101-3906, United States. The biotechnology company can be reached via phone at +1-206-2197815.
MarketBeat Community Rating for Dendreon (OTCMKTS DNDNQ)
MarketBeat's community ratings are surveys of what our community members think about Dendreon and other stocks. Vote "Outperform" if you believe DNDNQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DNDNQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
